Vermillion (NASDAQ: VRML) and InVitae (NYSE:NVTA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.
Earnings and Valuation
This table compares Vermillion and InVitae’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vermillion||$2.64 million||42.05||-$14.96 million||($0.20)||-9.25|
|InVitae||$25.05 million||21.24||-$100.25 million||($2.56)||-3.93|
This is a summary of recent ratings and price targets for Vermillion and InVitae, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vermillion presently has a consensus price target of $2.25, suggesting a potential upside of 21.62%. InVitae has a consensus price target of $14.50, suggesting a potential upside of 44.28%. Given InVitae’s higher probable upside, analysts plainly believe InVitae is more favorable than Vermillion.
Volatility and Risk
Vermillion has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, InVitae has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.
This table compares Vermillion and InVitae’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
34.9% of Vermillion shares are owned by institutional investors. Comparatively, 64.7% of InVitae shares are owned by institutional investors. 3.7% of Vermillion shares are owned by company insiders. Comparatively, 9.9% of InVitae shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
InVitae beats Vermillion on 9 of the 13 factors compared between the two stocks.
Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company’s products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.